Global Fecal Transplant Treatment 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI06258935

Publication Date:

June 25, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Fecal Transplant Treatment market size is predicted to grow from US$ 1191 million in 2025 to US$ 1609 million in 2031; it is expected to grow at a CAGR of 5.1% from 2025 to 2031.
Fecal transplant treatment is a therapy that transplants functional flora from the feces of healthy donors into the patient's intestines to rebuild the balance of intestinal microorganisms and treat intestinal and extraintestinal diseases. Its core principle is to use healthy flora to inhibit pathogenic microorganisms, repair intestinal barrier function and regulate the immune system, and improve the pathological state caused by flora imbalance through flora transplantation. Fecal transplant treatment is suitable for exploratory treatment of Clostridium difficile infection (CDI), inflammatory bowel disease (IBD) (ulcerative colitis, Crohn's disease), irritable bowel syndrome (IBS), metabolic syndrome (obesity, diabetes), neurological diseases (autism, Parkinson's disease), etc.
From the perspective of the global market, fecal transplant treatment continues to develop. North America dominates the market, and companies such as OpenBiome and Finch Therapeutics are promoting commercialization. The European Union classifies FMT as an "advanced therapeutic medicinal product (ATMP)" and requires standardized production. The United Kingdom and the Netherlands are leading in clinical trials and flora construction. In the Asia-Pacific region, the research progress in China and India is accelerating, but it will take a long time to achieve commercialization. The intensification of antibiotic resistance, breakthroughs in microbiome research, and the continuous improvement of regulatory policies are all driving the continuous development of fecal transplantation therapy. Manufacturers' competition focuses on standardized production and expanded indications. However, safety disputes, regulatory complexity, and patient acceptance all limit the rapid development of fecal transplantation therapy. In general, fecal microbial transplantation is a milestone in microbiome medicine, and its commercialization potential is closely related to the depth of intestinal flora research and the maturity of the regulatory framework.
The 鈥淔ecal Transplant Treatment Industry Forecast鈥� looks at past sales and reviews total world Fecal Transplant Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Fecal Transplant Treatment sales for 2025 through 2031. With Fecal Transplant Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Fecal Transplant Treatment industry.
This Insight Report provides a comprehensive analysis of the global Fecal Transplant Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Fecal Transplant Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Fecal Transplant Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Fecal Transplant Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Fecal Transplant Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Fecal Transplant Treatment market by product type, application, key players and key regions and countries.
Segmentation by Type:
Transcolonoscopic Transplantation
Nasoenteric Tube Perfusion
Oral Capsule
Segmentation by Application:
Clostridium Difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Irritable Bowel Syndrome (IBS)
Metabolic Syndrome
Neurological Diseases
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Enterome
Ferring Pharmaceuticals
Finch Therapeutics Group
MaaT Pharma
Seres Therapeutics
OpenBiome
Qualigen Therapeutics
Vedanta Biosciences

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Fecal Transplant Treatment 麻豆原创 Size (2020-2031)
2.1.2 Fecal Transplant Treatment 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Fecal Transplant Treatment by Country/Region (2020, 2024 & 2031)
2.2 Fecal Transplant Treatment Segment by Type
2.2.1 Transcolonoscopic Transplantation
2.2.2 Nasoenteric Tube Perfusion
2.2.3 Oral Capsule
2.3 Fecal Transplant Treatment 麻豆原创 Size by Type
2.3.1 Fecal Transplant Treatment 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Fecal Transplant Treatment 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Fecal Transplant Treatment Segment by Application
2.4.1 Clostridium Difficile Infection (CDI)
2.4.2 Inflammatory Bowel Disease (IBD)
2.4.3 Irritable Bowel Syndrome (IBS)
2.4.4 Metabolic Syndrome
2.4.5 Neurological Diseases
2.4.6 Others
2.5 Fecal Transplant Treatment 麻豆原创 Size by Application
2.5.1 Fecal Transplant Treatment 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Fecal Transplant Treatment 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Fecal Transplant Treatment 麻豆原创 Size by Player
3.1 Fecal Transplant Treatment 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Fecal Transplant Treatment Revenue by Player (2020-2025)
3.1.2 Global Fecal Transplant Treatment Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Fecal Transplant Treatment Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Fecal Transplant Treatment by Region
4.1 Fecal Transplant Treatment 麻豆原创 Size by Region (2020-2025)
4.2 Global Fecal Transplant Treatment Annual Revenue by Country/Region (2020-2025)
4.3 Americas Fecal Transplant Treatment 麻豆原创 Size Growth (2020-2025)
4.4 APAC Fecal Transplant Treatment 麻豆原创 Size Growth (2020-2025)
4.5 Europe Fecal Transplant Treatment 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Fecal Transplant Treatment 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Fecal Transplant Treatment 麻豆原创 Size by Country (2020-2025)
5.2 Americas Fecal Transplant Treatment 麻豆原创 Size by Type (2020-2025)
5.3 Americas Fecal Transplant Treatment 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Fecal Transplant Treatment 麻豆原创 Size by Region (2020-2025)
6.2 APAC Fecal Transplant Treatment 麻豆原创 Size by Type (2020-2025)
6.3 APAC Fecal Transplant Treatment 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Fecal Transplant Treatment 麻豆原创 Size by Country (2020-2025)
7.2 Europe Fecal Transplant Treatment 麻豆原创 Size by Type (2020-2025)
7.3 Europe Fecal Transplant Treatment 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Fecal Transplant Treatment by Region (2020-2025)
8.2 Middle East & Africa Fecal Transplant Treatment 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Fecal Transplant Treatment 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Fecal Transplant Treatment 麻豆原创 Forecast
10.1 Global Fecal Transplant Treatment Forecast by Region (2026-2031)
10.1.1 Global Fecal Transplant Treatment Forecast by Region (2026-2031)
10.1.2 Americas Fecal Transplant Treatment Forecast
10.1.3 APAC Fecal Transplant Treatment Forecast
10.1.4 Europe Fecal Transplant Treatment Forecast
10.1.5 Middle East & Africa Fecal Transplant Treatment Forecast
10.2 Americas Fecal Transplant Treatment Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Fecal Transplant Treatment Forecast
10.2.2 Canada 麻豆原创 Fecal Transplant Treatment Forecast
10.2.3 Mexico 麻豆原创 Fecal Transplant Treatment Forecast
10.2.4 Brazil 麻豆原创 Fecal Transplant Treatment Forecast
10.3 APAC Fecal Transplant Treatment Forecast by Region (2026-2031)
10.3.1 China Fecal Transplant Treatment 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Fecal Transplant Treatment Forecast
10.3.3 Korea 麻豆原创 Fecal Transplant Treatment Forecast
10.3.4 Southeast Asia 麻豆原创 Fecal Transplant Treatment Forecast
10.3.5 India 麻豆原创 Fecal Transplant Treatment Forecast
10.3.6 Australia 麻豆原创 Fecal Transplant Treatment Forecast
10.4 Europe Fecal Transplant Treatment Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Fecal Transplant Treatment Forecast
10.4.2 France 麻豆原创 Fecal Transplant Treatment Forecast
10.4.3 UK 麻豆原创 Fecal Transplant Treatment Forecast
10.4.4 Italy 麻豆原创 Fecal Transplant Treatment Forecast
10.4.5 Russia 麻豆原创 Fecal Transplant Treatment Forecast
10.5 Middle East & Africa Fecal Transplant Treatment Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Fecal Transplant Treatment Forecast
10.5.2 South Africa 麻豆原创 Fecal Transplant Treatment Forecast
10.5.3 Israel 麻豆原创 Fecal Transplant Treatment Forecast
10.5.4 Turkey 麻豆原创 Fecal Transplant Treatment Forecast
10.6 Global Fecal Transplant Treatment Forecast by Type (2026-2031)
10.7 Global Fecal Transplant Treatment Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Fecal Transplant Treatment Forecast
11 Key Players Analysis
11.1 Enterome
11.1.1 Enterome Company Information
11.1.2 Enterome Fecal Transplant Treatment Product Offered
11.1.3 Enterome Fecal Transplant Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Enterome Main Business Overview
11.1.5 Enterome Latest Developments
11.2 Ferring Pharmaceuticals
11.2.1 Ferring Pharmaceuticals Company Information
11.2.2 Ferring Pharmaceuticals Fecal Transplant Treatment Product Offered
11.2.3 Ferring Pharmaceuticals Fecal Transplant Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Ferring Pharmaceuticals Main Business Overview
11.2.5 Ferring Pharmaceuticals Latest Developments
11.3 Finch Therapeutics Group
11.3.1 Finch Therapeutics Group Company Information
11.3.2 Finch Therapeutics Group Fecal Transplant Treatment Product Offered
11.3.3 Finch Therapeutics Group Fecal Transplant Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Finch Therapeutics Group Main Business Overview
11.3.5 Finch Therapeutics Group Latest Developments
11.4 MaaT Pharma
11.4.1 MaaT Pharma Company Information
11.4.2 MaaT Pharma Fecal Transplant Treatment Product Offered
11.4.3 MaaT Pharma Fecal Transplant Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 MaaT Pharma Main Business Overview
11.4.5 MaaT Pharma Latest Developments
11.5 Seres Therapeutics
11.5.1 Seres Therapeutics Company Information
11.5.2 Seres Therapeutics Fecal Transplant Treatment Product Offered
11.5.3 Seres Therapeutics Fecal Transplant Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Seres Therapeutics Main Business Overview
11.5.5 Seres Therapeutics Latest Developments
11.6 OpenBiome
11.6.1 OpenBiome Company Information
11.6.2 OpenBiome Fecal Transplant Treatment Product Offered
11.6.3 OpenBiome Fecal Transplant Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 OpenBiome Main Business Overview
11.6.5 OpenBiome Latest Developments
11.7 Qualigen Therapeutics
11.7.1 Qualigen Therapeutics Company Information
11.7.2 Qualigen Therapeutics Fecal Transplant Treatment Product Offered
11.7.3 Qualigen Therapeutics Fecal Transplant Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Qualigen Therapeutics Main Business Overview
11.7.5 Qualigen Therapeutics Latest Developments
11.8 Vedanta Biosciences
11.8.1 Vedanta Biosciences Company Information
11.8.2 Vedanta Biosciences Fecal Transplant Treatment Product Offered
11.8.3 Vedanta Biosciences Fecal Transplant Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Vedanta Biosciences Main Business Overview
11.8.5 Vedanta Biosciences Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.